Bioluminescence resonance energy transfer using luciferase-immobilized quantum dots for self-illuminated photodynamic therapy

• Published in: Biomaterials Vol. 34; no. 4; pp. 1204 - 1212
• Main Authors: Hsu, Chia-Yen, Chen, Ching-Wen, Yu, Hsiu-Ping, Lin, Yan-Fu, Lai, Ping-Shan
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.01.2013
• Subjects: Advanced Basic Science; Bioluminescence; Biomedical materials; Cell Line, Tumor; Dentistry; Energy transfer; Enzymes, Immobilized; Fluorescence Resonance Energy Transfer - methods; Humans; Illumination; In vivo; Light sources; Luciferases - pharmacokinetics; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Mesoporphyrins - administration & dosage; Nanostructure; Photochemotherapy - methods; Photodynamic therapy; Photosensitizing Agents - administration & dosage; Quantum Dots; Renilla; Surgical implants; Treatment Outcome; Tumors; Wavelengths; Illumination; Bioluminescence; Photodynamic therapy; Energy transfer; In vivo
• DOI: 10.1016/j.biomaterials.2012.08.044
• ISSN: 0142-9612

Abstract Photodynamic therapy (PDT) is an innovative method for cancer treatment that involves the administration of a photosensitizing agent followed by exposure to visible light. An appreciable amount of a particular light source is a key to activate photosensitizers in PDT. However, the external excitation light source is a problem for clinical application because of the limitation of tissue-penetrating properties. Additionally, the wavelength of laser emission should match the absorption wavelength of each photosensitizer for efficient generation of reactive oxygen species and cell killing. In this study, Renilla luciferase-immobilized quantum dots-655 (QD-RLuc8) was used for bioluminescence resonance energy transfer (BRET)-mediated PDT to resolve these problems. The bioluminescent QD-RLuc8 conjugate exhibits self-illumination at 655 nm after coelenterazine addition, which can activate the photosensitizer, Foscan® -loaded micelles for PDT. Our results show that BRET-mediated PDT by QD-RLuc8 plus coelenterazine (20 μg/mL) successfully generated reactive oxygen species (40.8%), killed ∼ 50% A549 cells at 2 μg/mL equivalent Foscan® in vitro and significantly delayed tumor growth in vivo due to cell apoptosis under TUNEL analysis without obvious weight loss. Based on immunohistochemical observations, the proliferating cell nuclear antigen (PCNA)-negative area of tumor sections after BRET-mediated PDT was obviously increased compared to the PDT-untreated groups without an external light source. We conclude that this nanotechnology-based PDT possesses several clinical benefits, such as overcoming light penetration issues and treating deeper lesions that are intractable by PDT alone.